natgillin/translations-raw huggingface dataset:
is selected from hydrogen, ethyl, fluoromethyl, difluoromethyl, methyl, and trifluoromethyl. 
R? je odabrano od vodik, etil, fluorometil, difluorometil, metil, i trifluorometil.
Headset apparatus according to claim 16 or 17 in which said articulation portion includes a third articulation limb (57) which is resiliently joined to the second articulation limb at a join therebetween such the third articulation limb may be moved from its quiescent position relative to the second articulation limb by resilient flexure and/or torsion of either limb and/or of the join therebetween wherein the third articulation limb extends from the second articulation limb in a direction generally transverse to the directions in which the first and second articulation limbs respectively extend. 
Slušalice prema zahtjevu 16 ili 17, naznačene time, da navedeni zglobno vezani odsječak obuhvaća treći zglobni krak (57) koji je elastično zglobno spojen na drugi zglobni krak (53) na međusobnom zglobnom spoju tako, da treći zglobni krak može biti pomaknut iz svojega mirnog položaja u odnosu na drugi zglobni krak, pomoću elastičnog pregibanja i/ili zavrtanja kraka i/ili međusobnog zglobnog spoja, pri čemu se treći zglobni krak proteže iz drugog zglobnog kraka u smjeru općenito poprečnom na smjerove u kojima se proteže prvi odnosno drugi zglobni krak.
The method as claimed in claim 1, wherein said electromagnetic beam has a specific power (P) ranging from 30 to 500 W per gram of powdered product. 
Postupak sukladno zahtjevu 1, pri čemu elektromagnetsko polje ima specifičnu snagu (P) opsega od 50 do 300 W po gramu praškastog proizvoda, poželjno oko 150 W po gramu praškastog proizvoda.
Composition according to claim 1 characterized by containing sucralfate and phospholipids in a weight ratio from about 1:0.5 to about 1:2. 
Smjesa prema zahtjevu 1 naznačena time što su sukralfat 1 fosfolipidi sadržani u masenom omjeru od oko 1:0.5 do oko 1:2.
heavy and light chains comprising the amino acid sequences of SEQ ID NO:46, and SEQ ID NO:48, 60, 62, or 64, respectively; or 
teške i lake lance koji sadrže aminokiselinske sljedove sa SEQ ID NO:46 odnosno SEQ ID NO:48, 60, 62 ili 64; ili
The IL-18BP gene was localized to the human chromosome 11, and no exon coding for a transmembrane domain could be found in the 8.3 kb genomic sequence comprising the IL-18BP gene. 
Gen za protein IL-18BP nalazi se na ljudskom kromosomu 11, a unutar njega nije nađen egzon koji kodira za transmembransku domenu nakon pretraživanja sekvence duljine 8.3 kb koja čini spomenuti gen.
The method of claim 1, wherein said subject has a fasting plasma glucose (FPG) level of greater than 100 mg/dl. 
(i) ima razinu glukoze u plazmi natašte (FPG) veću od 100 mg / dl;
A humanized antibody heavy and/or light chain(s) and/or a humanized antibody, or a derived compound or functional fragment of same, and/or a composition according to claim 23, characterized in that said cancer is a cancer selected among prostate cancer, osteosarcoma, lung cancer, breast cancer, endometrial cancer, multiple myeloma, ovarian cancer, pancreatic cancer and colon cancer. 
Humanizirano antitijelo ili njegov funkcionalni fragment i/ili pripravak prema patentnom zahtjevu 16, naznačen time da je rečeni karcinom odabran od sljedećih: karcinom prostate, osteokarcinom, karcinom pluća, karcinom dojke, karcinom endometrija, multipla mieloma, karcinom jajnika, karcinom pankreasa i karcinom crijeva.
treating a compound of formula IV.1 with a compound of formula V.1 to form a compound of formula IIIb.1; 
- obrade spoja formule IV.1 spojem formule V.1 kako bi se dobilo spoj formule IIIb. 1;
is selected from the group consisting of hydrogen, deuterium, C1-C6 linear or branched chain alkyl, C1-C6 linear or branched chain perfluoroalkyl, halogen, and cyano; 
R3; se bira iz skupine koju čine vodik, deuterij, Cy-Cg alkil s nerazgranatim ili razgranatim lancem, C;-Cg perfluoralkil s nerazgranatim ili razgranatim lancem, halogen, te cijano;
A pharmaceutical composition as claimed in claim 1, wherein the calcium salt of a weak acid is tribasic calcium phosphate, the lubricant is hydrogenated castor oil, and sorbitol as a diluting agent is present in a mixture with another diluting agent, which is alginic acid. 
Farmaceutska smjesa prema zahtjevu 1, gdje je kalcijeva sol slabe kiseline tribazični kalcijev fosfat, lubrikant je hidrogenirano rTicinusovo ulje, 1 sorbitol kao punilo je prisutan u mješavini s drugim punilo koje je alginska kiselina.
This advantage is at least in part due to the stability of the hydrogel which in turn is at least in part due to the washing process. 
Ova prednost je barem u jednom dijelu zbog stabilnosti hidrogela, a ova stabilnost hidrogela je zatim barem u jednom dijelu zbog postupka ispiranja.
The object of the invention is further to introduce wood pressure impregnated with a wood preservative containing vegetable oil the wood preservative of which does not bleed onto the surface of wood during the use of wood, even though a large amount of the wood preservative containing vegetable oil has been impregnated in the wood. DESCRIPTION OF THE INVENTION In the method according to the invention wood is pressure impregnated with a wood preservative containing vegetable oil without drying agents or agents causing polymerization and before starting the pressure stage, wood is heated so that at least part of its inner parts heat to a temperature of at least 50° C. and after the pressure impregnation, vacuum is formed in the surrounding space of wood and simultaneously the surface layers of wood are heated to a temperature higher than the boiling point of water at least 75 minutes for removing wood preservative from the surface layers of wood. 
HR P20151363 T1 PATENTNI ZAHTJEVI Postupak za impregnaciju drva ili proizvoda od drveta pomoću konzervansa za drvo bez agensa koji sadrže boju ili agensa koji uzrokuju polimerizaciju, navedeni konzervans za drvo sadrži biljna ulja poput: sirove tekuće smole, smole i/ili masnih kiselina odvojenih iz nje ili iz smjese istih; u kojem postupku, prije otpočinjanja faze impregnacije pod pritiskom, navedeno drvo se zagrijava na način da je barem dio njegovih unutarnjih dijelova zagrijan na temperaturu od barem 50"C, naznačena formiranjem, nakon navedenog koraka impregnacije pod pritiskom, vakuuma u prostoru koji okružuje navedeno drvo te istovremeno zagrijavanjem površinskih slojeva navedenog drveta pomoću pare na temperaturu višu od točke vrelišta vode te održavanjem ovog okruženja navedenog drveta barem 75 minuta kako bi se uklonilo navedeni konzervans s površinskih slojeva navedenog drveta.
a T cell receptor B-chain comprising all three of the CDR sequences of a T cell receptor B-chain of SEQ ID NO: x+1; wherein x selected from the group consisting of 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28 and 
B-lanac T staničnog receptora koji sadrži sve tri CDR sekvence B-lanca T staničnog receptora od SEK ID BR: x + 1; naznačen time, da je x odabran iz skupine sastavljene od 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 i 28 i
A method of inhibiting PCSK9 expression in a cell, the method comprising: 
Postupak inhibiranja ekspresije PCSKO u stanici, naznačen time što postupak sadrži:
The method according to claim 1, wherein the symptom or disorder associated with calcium imbalance is pain-related and administration of apoaequorin to said subject alleviates pain in the subject. 
Uporaba apoekvorina prema zahtjevu 1, naznačena time, da je za proizvodnju nutraceutskog sastava za liječenje poremećaja iz zahtjeva 1 povezanog sa spavanjem, energijom, raspoloženjem, bolom ili pamćenjem kod subjekta, kojemu se pritom daje spomenuti nutraceutski sastav.
The aqueous suspension preparation of claim 1, wherein the surfactant is present in a concentration of 0.25% to 1% in the aqueous suspension preparation. 
Pripravak u obliku vodene suspenzije u skladu s patentnim zahtjevom 1, naznačen time što je tenzid prisutan u koncentraciji od 0,25 % do 1 % u pripravku u obliku vodene suspenzije.
Process for bacterial stabilizing an aqueous preparation, said preparation comprising at least one natural calcium carbonate, synthetic, precipitated calcium carbonate, kaolin, talcum, aluminium hydroxide, aluminium silicate, titanium dioxide or mixtures thereof and at least one strain of bacteria selected from the group consisting of Methylobacteria and Pseudomonas which is resistant to, tolerant to and/or degrades aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in absence of lithium ions, wherein the process comprises the steps of: 
Postupak za bakterijsku stabilizaciju vodenog pripravka, te navedeni pripravak sadrži barem jedan prirodni kalcijev karbonat, sintetski, istaloženi kalcijev karbonat, kaolin, talk, aluminijev hidroksid, aluminijev silikat, titanijev dioksid ili njihove smjese i barem jedan soj bakterija koji je odabran iz skupine koju čine bakterije Metilobacteria i Pseudomonas, koje su rezistentne na, tolerantne na i/ili degradiraju biocide koji oslobađaju aldehid i/ili biocide s jednom ili više aldehidnih skupina u odsutnosti litijevih iona, naznačen time da postupak obuhvaća korake:
The method of claim 1, wherein, when the available intra prediction mode is a DC mode, the two additional intra prediction modes are a planar mode and the vertical mode. 
Metoda prema zahtjevu 1, naznačena time da je dostupni unutarokovirni načina predviđanja DC način, dva dodatna unutarokovirna načina predviđanja uključuje planarni 1 vertikalni način.
The antibody or fragment thereof for use according to Claim 9, wherein the cancer is leukemia, breast cancer, endometrial cancer, prostate cancer, ovarian cancer, colorectal cancer, hepatocellular cancer, renal cancer, multiple myeloma, or hodgkin's lymphoma. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 7, naznačeno time što je rak leukemija, rak dojke, rak endometrija, rak prostate, rak jajnika, kolorektalni rak, hepatocelularni rak, rak bubrega, multipli mielom ili Hodgkinov limfom.
Optionally, the crystallization process may be repeated as necessary to obtain the desired compactin purity. 
Po izboru, postupak kristalizacije može se ponoviti koliko je potrebno puta da se dobije kompaktin željene čistoće.
This is evidenced by the results of the micronization of batches C3-C5, which furnished the micronized batches M4, M5, M6, and M7 (examples 12-15). 
Ovo je dokazano rezultatima mikronizacije serija C3-C5, koje su opskrbile mikronizirane serije M4, MS, M6, i M7 (primjeri 12-15).
A plurality of slidable and/or rotatable parts may be provided in the packaging. 
U pakiranju može biti predviđen veći broj dijelova koji mogu klizati i/ili rotirati.
The compound or a salt thereof according to claim 1, wherein said compound is 2-fluoro-3-[2-(3-methoxyazetidin-1-yl)pyrimidin-5-yl]benzyl carbamimidoylcarbamate, or a salt thereof. 
Spoj ili njegova sol prema zahtjevu 1, naznačen/a time, da navedeni spoj je 2-fluoro-3-[2-(3-metoksiazetidin-1-iI)pirimidin-5-il]benzil-karbamimidoilkarbamat, ili njegova sol.
A pharmaceutical composition according to any of claims 32 - 40, wherein the high molecular weight PEO comprises at least about 80% (by weight) of the tablet. 
Oblik doziranja s produljenim otpuštanjem prema zahtjevima od 1 do 11, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida.
The method of any one of claims 1 to 9 wherein the monoclonal antibody, or antigen-binding fragment thereof, is selected from the group consisting of HER2 antibodies, EGFR antibodies, CD20 antibodies, CD22 antibodies, VEGF antibodies, VEGF receptor antibodies, IgE antibodies, Apo-2 receptor antibodies, and TNF-alpha antibodies. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da je monoklonsko protutijelo, ili njegov fragment koji veže antigen, odabrano iz skupine koja se sastoji od sljedećih: HER2-protutijela, EGFR-protutijela, CD20-protutijela, CD22-protutijela, VEGF-protutijela, VEGF-receptor-protutijela, IgE-protutijela, Apo-2-receptor-protutijela, i TNF-alfa-protutijela.
FIG. 2 shows a side view, with parts in section and parts removed for clarity, of a portion of the FIG. 
Slika 2 prikazuje pogled sa strane dijela Slike 1 članka za miješanje, s dijelovima u presjeku, i radi jasnoće, bez odstranjenih dijelova;
treatment of organic disorders associated with NO formation: hypertension, hypotension, anaphylaxis, circulatory and septic shock, aggregation of thrombocytes; 
- liječenje sljedećih organskih poremećaja povezanih s NO-tvorbama: hipertenzija, hipotenzija, anafilaksa, cirkulacijski 1 septički šok, agregacija trombocita;
The water treatment facility of claim 5, wherein the water treatment device is a membrane separation device. 
Uređaj za obradu vode u skladu s patentnim zahtjevom 3, naznačen time, da je uređaj za obradu vode (3) membranski uređaj za odvajanje.
The foregoing and other objects are solved by the provision of a process for remineralization of water comprising the steps of (a) providing feed water, and (b) injecting gaseous carbon dioxide and a slurry into the feed water, wherein the slurry comprises micronized calcium carbonate. 
PATENTNI ZAHTJEVI Postupak za remineralizaciju vode koji sadrži korake: a) dobavljanje ulazne vode, te b) injektiranje plinovitog ugljik dioksida 1 mulja u ulaznu vodu, pri čemu mulj sadrži mikronizirani kalcij karbonat, gdje kalcij karbonat ima veličinu čestica od 0.1 do 100 um.
The composition according to claim 3, wherein the preservative is present in an amount of 0.01 g to 0.5 g based on 100 ml of the composition. 
Pripravak prema zahtjevu 3, naznačen time da je konzervans prisutan u količini od 0.01 g do 0.5 g, bazirano na 100 ml pripravka.
for a compound of Formula I where X is O, coupling a corresponding compound having the formula V 
(d) za spoj s formulom I gdje X je O, sparivanje odgovarajućeg spoja koji ima formulu V u RR
The pharmaceutical composition of claim 5 further comprising a second therapeutic agent selected from an anti-viral agent or an anti-tumor/cancer agent 
Farmaceutski sastav patentnog zahtjeva 2 dalje obuhvaća drugi terapeutski agens izabran od anti-viralnog agensa ili anti-tumorskog/kancerogenog agensa.
Granular material is received in the outer chamber (14) for absorbing pressure forces acting on the volume element (10) from the direction of the outer chamber (14). 
Element za napuhavanje (10) u skladu s patentnim zahtjevom 1, naznačen time što unutarnja komora (12) je u najmanju ruku pretežno okružena vanjskom komorom (14) na vanjskom obodu.
The aqueous pharmaceutical suspension according to claim 79, wherein the flavoring agent is artificial raspberry cream flavor or artificial orange cream flavor. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 79, naznačena time što sredstvo za aromatiziranje je umjetna aroma kreme od malina ili umjetna aroma kreme od naranče.
A combination according to claim 3 wherein the B2 agonist is selected from the group comprising formoterol, salmeterol and QAB-149 optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Celgene) i MN-001 (ex. Kvorin), po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
alkoxyalkyl; and hydroxyalkyl; R10b is selected from the group consisting of hydrogen and alkyl; or 
R! je odabran iz grupe koja se sastoji od: a) - vodika; b) alkila;
Combination of drugs and compounds of the invention 
Datum objave europske prijave patenta:
Accordingly, there is a need for the development of compounds capable of improving the treatment of depression and other serotonin related diseases. 
Prema tomu postoji potreba za razvijanjem spojeva koji su u stanju poboljšati liječenje depresije I drugih bolesti povezanih sa serotoninom.
An enantiomerically enriched mixture including the compound according to claim 1. 
Enantiomerno obogaćena smjesa, naznačena time što sadrži spoj u skladu s patentnim zahtjevom 1.
contacting a compound in the presence of which less of said complex is formed in step (c) in vitro with a mammalian enteroendocrine cell; and 
(d) stavljanje u kontakt spoja u prisutnosti u kojoj se formira manje kompleksa iz koraka (c) in vitro s enteroendokrinom stanicom sisavca; te
The method of claim 8 wherein the quenching agent is L-cysteine, and is preferably added to result in a final concentration of about 10 mM and the conditions comprise a time period of about 60 minutes, a temperature of about 22°C, the absence of light and with stirring. 
Postupak prema zahtjevu 8, pri čemu je agens za gašenje L-cistein, i poželjno je dodan kako bi rezultirao krajnjom koncentracijom od oko 10 mM i uvjeti sadrže vremenski period od oko 60 minuta, temperaturu od oko 22 "€, odsutnost svjetla i s miješanjem.
The method of claim 14, wherein the method comprises coating the paper product with at least about 25 wt. % of a co-processed microfibriilated cellulose and inorganic particulate material composition on the paper product. 
Papirni proizvod u skladu s patentnim zahtjevom 8, naznačen time što ima prvi sjaj veći od drugog sjaja obloženog papirnog proizvoda koji ne sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala.
The vaccine of claim 4, wherein a) the bacterial antigen is whole killed bacteria, live attenuated bacteria or bacterial purified proteins; or b) the viral antigen is whole killed virus, live attenuated virus or viral purified proteins. 
bakterijski antigen su cijele ubijene bakterije, žive oslabljene bakterije ili pročišćeni bakterijski proteini; ili virusni antigen su cijeli ubijeni virus, živi oslabljeni virus ili pročišćeni virusni proteini.
In another aspect, the present invention provides compounds of formula (L) in free or salt form, wherein 
U drugom obliku, predloženi izum osigurava spojeve formule (1) u slobodnom obliku ili u obliku soli, u kojoj formuli
Randomisation of the animals: 
Broj objave europskog patenta:
Use of the magnetically oriented design produced according to any one of claims 13 to 16, as a security element on bank notes, value documents, identity documents, cards, tax stamps, labels, as well as for products. 
Uporaba magnetski usmjerenog uzorka izrađenog sukladno bilo kojem patentnom zahtjevu 13 do 16, naznačena time, da navedena uporaba služi za izradu sigurnosnog elementa na novčanicama, vrijednosnim dokumentima, identifikacijskim dokumentima, karticama, biljezima, oznakama ili proizvodima.
The amorphous solid dispersion for use according to Claim 1, wherein the previous treatment for breast cancer is selected from lumpectomy, partial mastectomy, segmental mastectomy, total mastectomy, modified radical mastectomy, external radiation, internal radiation, methotrexate, paclitaxel albumin-stabilized nanoparticle formulation, ado-trastuzumab emtansine, doxorubicin, fluorouracil, everolimus, anastrozole, exemestane, capecitabine, cyclophosphamide, docetaxel, epirubicin, exemestane, toremifene, fulvestrant, letrozole, gemcitabine, trastuzumab, ixabepilone, lapatinib, tamoxifen, pertuzumab and toremifene, or mixtures thereof. 
Disperzija amorfne krutine, namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što se prethodno liječenje raka dojke bira između tilektomije, djelomične mastektomije, segmentalne mastektomije, potpune mastektomije, modificirane radikalne mastektomije, vanjskog zračenja, unutarnjeg zračenja, metotreksata, formulacija albuminom stabiliziranih nanočestica paklitaksela, ado-trastuzumab-emtanzina, doksorubicina, fluoruracila, everolimusa, anastrozola, eksemestana, kapecitabina, ciklofosfamida, docetaksela, epirubicina, eksemestana, toremifena, fulvestranta, letrozola, gemcitabina, trastuzumaba, iksabepilona, lapatiniba, tamoksifena, pertuzumaba i toremifena, ili njihovih kombinacija.
Percentage of the herbicidal action of component A) at an application rate of a; 
X = postotak herbicidnog djelovanja komponente A) sa stopom primjene a;
in part (a), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:113 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:112; 
VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 113 i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 112;
When the reagent used is a carboxyl anhydride, an exemplary procedure (as shown in FIG. 18) is as follows. 
Kada je reagens koji se koristi karboksil anhidrid, slijedi postupak koji je prikazan kao primjer (kao što je prikazano na slici 18).
a blending apparatus operable to blend used oil and fresh cylinder oil, an internal combustion engine comprising at least one cylinder, 
sredstva za miješanje 5 za miješanje rabljenog ulja i svježeg cilindarskog ulja, motor s unutrašnjim izgaranjem 1 koji sadrži barem jedan cilindar 10
A PARP inhibitor or a therapeutically acceptable salt thereof, wherein the PARP inhibitor is 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, for use in treating cancer or inhibiting tumor growth in a mammal, wherein the cancer is a CNS tumor, and wherein said PARP inhibitor is to be administered in combination with radiotherapy. 
PATENTNI ZAHTJEVI 1. Inhibitor PARP-a ili njegova terapijski prihvatljiva sol, naznačen time, da je inhibitor PARP-a 2-[(2R)-2- metilpirolidin-2-11]-1H-benzimidazol-4-karboksamid namijenjen liječenju karcinoma ili sprječavanju rasta tumora u sisavca, pri čemu je karcinom tumor središnjeg živčanog sustava, a navedeni inhibitor PARP-a primjenjuje se u kombinaciji s radioterapijom.
The salt of Claim 4 characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at -64.5, -114.7, -136.3, and -146.2 ppm. 
Sol iz Zahtjeva 4, naznačena time, da spektar nuklearne rezonance krutog fluorina-19 MAS pokazuje signale na- 64.5, -114.7, -136.3 i -146.7 ppm
The method of claim 5 wherein the mirror plug further comprises a set of mirror plug coils wrapped around a constriction in the passageway between each of the first and second formation sections and the first and second divertors. The method of claim 1 wherein the mirror plug coils are compact pulsed mirror coils. 
Sustav prema zahtjevu 6, naznačen time, da zrcalni utikač dodatno obuhvaća komplet zrcalnih zavojnica omotanih oko tjesnaca (442) u prolaznom kanalu između svakog od prvog i drugog tvorbenog dijela (200) 1 prvog i drugog preusmjerivača (300).
R6, at each occurrence, is independently alkyl, cycloalkyl, aryl or heteroaryl, all of which may be optionally substituted with with R7, R7a, R7b, and R7c; and 
, uvijek kada se pojavljuje, je nezavisno alkil, cikloalkil, aril ili heteroaril, od čega sve po izboru može biti supstituirano s R7, R7a, R7b, i R7c; i
The compound thus obtained can possibly be salified with entirely conventional methods in the art. 
Spoj koji je tako dobiven može po mogućnosti biti preveden u sol s potpuno konvencionalnim stručnim postupcima.